IP Library Granted Patent US 8,226,951
Granted Patent B2
US 8,226,951 · App. 13/153,587 · Granted Jul 24, 2012

Methods for treating bone cancer by administering a nerve growth factor antagonist antibody

Assignee: Pfizer Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,226,951
App. No.
13/153,587
Granted
Jul 24, 2012
Kind
B2
Abstract

The invention features methods and compositions for preventing or treating bone cancer pain including cancer pain associated with bone metastasis by administering an antagonist of nerve growth factor (NGF). The NGF antagonist may be an anti-NGF (such as anti-hNGF) antibody that is capable of binding hNGF.

Claims (12)

1. A method for treating bone cancer pain in an individual comprising administering to the individual an effective amount of an anti-nerve growth factor (NGF) antagonist antibody, wherein the anti-NGF antagonist antibody comprises:

a heavy chain variable region (VH) comprising a VH CDR1, VH CDR2, and VH CDR3 of the VH sequence shown in SEQ ID NO: 1; and

a light chain variable region (VL) comprising a VL CDR1, VL CDR2, and VL CDR3 of the VL sequence shown in SEQ ID NO: 2.

2. The method of claim 1 , wherein the VH CDR1, VH CDR2, and VH CDR3 of the anti-NGF antagonist antibody are Kabat, Chothia, or a combination of Kabat and Chothia CDRs of the VH sequence shown in SEQ ID NO: 1.

3. The method of claim 1 , wherein the VH region comprises the amino acid sequence shown in SEQ ID NO: 1 or a variant with one or several conservative amino acid substitutions in residues that are not within a CDR and the VL region comprises the amino acid sequence shown in SEQ ID NO: 2 or a variant thereof with one or several amino acid substitutions in amino acids that are not within a CDR.

4. The method of claim 2 , wherein the bone cancer pain is from cancer originated in bone.

5. The method of claim 2 , wherein the bone cancer pain is from osteosarcoma.

6. The method of claim 2 , wherein the bone cancer pain is from cancer metastasized to bone.

7. The method of claim 2 , wherein the bone cancer pain is from prostate cancer metastasized to bone.

8. The method of claim 2 , wherein the bone cancer pain is from breast cancer metastasized to bone.

9. The method of claim 2 , wherein the bone cancer pain is from lung cancer metastasized to bone.

10. The method of claim 2 , wherein the bone cancer pain is from sarcoma metastasized to bone.

Assignments (4)
ASSIGNEE ADDRESS CORRECTION Recorded Mar 31, 2023
From: RINAT NEUROSCIENCE CORP. & REGENTS OF THE UNIVERSITY OF MINNESOTA
To: RINAT NEUROSCIENCE CORP. & REGENTS OF THE UNIVERSITY OF MINNESOTA
Reel/Frame 063210/0754 →
CONFIRMATORY LICENSE Recorded Nov 1, 2013
From: UNIVERSITY OF MINNESOTA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 031532/0695 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2013
From: MANTYH, PATRICK W.
To: REGENTS OF THE UNIVERSITY OF MINNESOTA
Reel/Frame 029988/0943 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2013
From: SHELTON, DAVID L.
To: RINAT NEUROSCIENCE CORP.
Reel/Frame 029989/0671 →
Continuity (6)
Continuation 12404759 · Mar 16, 2009
Continuation 11800124 · May 3, 2007
Continuation 11102201 · Apr 7, 2005
Provisional Application 60620654 · Oct 19, 2004
Provisional Application 60560781 · Apr 7, 2004
Related Publication 20110243961A1 · Oct 6, 2011